$OPRX News

OptimizeRx's Electronic Health Record Network Integrated By DeepIntent

Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $11

B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $10

Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $7

Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14

OptimizeRx Corp (NASDAQ:OPRX) Beats Q1 Estimates But Slashes 2026 Revenue Guidance

OptimizeRx Corporation (OPRX) Q1 2026 Earnings Call Transcript

OptimizeRx Reports Q1 2026 Results: Full Earnings Call Transcript

OptimizeRx Lowers FY2026 Sales Guidance from $109.000M-$114.000M to $95.000M-$100.000M vs $111.438M Est

OptimizeRx Q1 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $19.844M Beat $18.353M Estimate

OptimizeRx Launches New Programmatic Connection Point Between OptimizeRx's Proprietary EHR Network And DSPs

Watching OptimizeRx; Hearing Zacks Under $10 Newsletter Picks Stock

Watching OptimizeRx; Hearing Zacks Under $10 Newsletter Picks Stock

OptimizeRx: Q4 Earnings Report Indicates Caution For 2026

Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $20

OptimizeRx shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.

OptimizeRx Warns Of Volatility From 'Most Favored Nation' Pricing Uncertainty

Assessing OptimizeRx: Insights From 4 Financial Analysts

Roth Capital Maintains Buy on OptimizeRx, Lowers Price Target to $18

B. Riley Securities Reiterates Buy on OptimizeRx, Lowers Price Target to $11